In vivo applications and toxicities of AAV-based gene therapies in rare diseases
Abstract Adeno-associated virus (AAV), renowned for its exceptionally low pathogenicity and significant efficacy in clinical gene therapy, has emerged as a leading delivery vector in the field of gene therapy. AAV can achieve stable gene expression in various tissues, which has made it a promising t...
Saved in:
| Main Authors: | Qian Zhao, Huifang Peng, Yujin Ma, Huijun Yuan, Hongwei Jiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-025-03893-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improved AAV9-based gene therapy design for SURF1-related Leigh syndrome with minimal toxicity
by: Qinglan Ling, et al.
Published: (2025-09-01) -
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial
by: Andrew D. Leavitt, et al.
Published: (2024-11-01) -
Effective AAV‐mediated gene therapy in a mouse model of ethylmalonic encephalopathy
by: Ivano Di Meo, et al.
Published: (2012-08-01) -
The Use of AAV Vector-based Gene Therapy in the Treatment of Ophthalmic Diseases. Literature Review
by: Z. A. Batyrova, et al.
Published: (2025-06-01) -
Investigating the In Vivo Effects of Anti-Prion Protein Nanobodies on Prion Disease with AAV Vector
by: Jingjing Zhang, et al.
Published: (2025-02-01)